The hedge fund manager John Paulson joins the pharmaceutical company's board after losing almost $2 billion on a bad bet on Valeant stock.
Andrew Left of Citron Research successfully shorted Valeant and other companies. Now he sees Nvidia as the latest target.
Valeant Pharmaceuticals is setting off buy signals after Bill Ackman's Pershing Capital pulled up stakes and took a massive loss. (VRX)
Apart from its notorious dumping of Valeant stock, the firm cut its holdings in snack maker Mondelez and Air Products and Chemicals.
Is it too little, too late for Valeant investors?
Learn more about Valeant Pharmaceuticals International Inc. and three of the top companies that Valeant owns or operates as subsidiaries.
For the first time, British investors will be able to invest in Bill Ackman's legendary fund via the London Stock Exchange.
Valeant Pharmaceuticals stock is in free fall and has drifted below $10 a share.
Bill Ackman has called his investment in Valeant a mistake, saying he misjudged the ability of Valeant’s former management team.
Analysts say recent FDA guidance could result in early competition for Valeant’s IBS-D drug Xifaxan, but company begs to differ.